Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avenciguat - Boehringer Ingelheim

Next Previous
Drug Profile

Avenciguat - Boehringer Ingelheim

Alternative Names: BI-685509

Latest Information Update: 18 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Skin disorder therapies; Urologics
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies; Portal hypertension; Renal failure; Systemic scleroderma

Most Recent Events

  • 30 Jan 2026 Boehringer Ingelheim completes a phase II trial in Systemic scleroderma in Australia, South Korea, Spain, Argentina, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Romania, Singapore, Sweden, Switzerland, Taiwan, Thailand, the UK, the US, India, Norway, Portugal and Turkey (PO) (NCT05559580)
  • 04 Nov 2024 Boehringer Ingelheim terminates a phase I pharmacokinetics trial in Liver disorders in USA (PO) due to sponsor's decision (NCT06272058)
  • 28 Aug 2024 No recent reports of development identified for phase-I development in Diabetic-nephropathies(In volunteers) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top